Neoadjuvant chemotherapy (NAC) resulted in histologic regression and downstaging and decreased the rate of incomplete resections among patients with operable colon cancer, according to results of the FOxTROT trial presented by Matthew T. Seymour, MD, of the National Institute for Health Research Clinical Research Network, on June 1.
The objectives of FOxTROT were to determine if NAC administration prior to surgery improves disease-free survival among patients with colon cancer. In addition, a substudy evaluated whether adding panitumumab to preoperative NAC for patients whose disease harbored wildtype KRAS would increase NAC anti-tumour activity (Abstract 3504).
Patients with operable, nonobstructed, radiologically staged T3 or T4 (N0-2) colon cancer without metastases were randomly assigned 2:1 to either the NAC group or the control group. Patients in the NAC group received 6 weeks of FOLFOX followed by surgery and then another 18 weeks of FOLFOX, whereas the control group underwent surgery and then received postoperative FOLFOX for 24 weeks.
Patients with wildtype KRAS tumours assigned to the NAC group had the option to be randomly assigned 1:1 to receive panitumumab during 6 weeks of NAC treatment. The protocol allowed for two other options: a total chemotherapy duration of 12 weeks instead of 24 weeks, or treatment with oxaliplatin and capecitabine (OxCap) instead of FOLFOX for patients who were not in the panitumumab substudy. The primary endpoint was 2-year freedom from recurrent or persistent disease. Secondary outcomes included downstaging, tumour regression, R0 resection rate, and perioperative safety.
A total of 1,052 patients were randomly assigned (698 to the NAC group and 354 to the control group). The overall median age was 65, and 64% of patients were male. The baseline characteristics of both treatment arms were well balanced. Surgery was performed in the majority of patients (98% in both groups). In both arms, 28% were to receive OxCap and 6% were to receive 12 weeks of postoperative chemotherapy. A significantly greater proportion of patients in the control group did not receive chemotherapy compared with the NAC group (27% vs. 4%; P < 0.0001) because their tumour was low risk (16%) or they were too ill/declined chemotherapy (11%).
There were no unexpected findings of chemotherapy-associated toxicity. Significantly more patients in the control arm experienced complications that necessitated additional surgery compared with patients receiving NAC (7.1% vs. 4.3%; P = 0.05). Higher numbers of patients in the control group also experienced anastomotic leak or intra-abdominal abscess compared with those in the NAC group (7.4% vs. 4.7%) or a complication prolonging their hospital stay (14.3% vs. 11.6%), but these data did not reach statistical significance.
“Preoperative chemotherapy did not increase surgical morbidity; in fact, there were fewer major surgical complications,” Dr. Seymour said.
The 2-year failure rate improved but was not statistically significant, with rates of 13.6% in the NAC group compared with 17.2% in the control group (HR 0.75, 95% CI [0.55, 1.04]; P = 0.08). The control recurrence rate of 17.2% was much lower than the estimates used when powering the study (25% to 32%). Other outcomes favoured NAC: risk of undergoing surgery without achieving R0, tumour stage/size at surgery, nodal stage at surgery, and tumour regression grade at surgery (all; P < 0.001). Results from a sensitivity analysis indicated that the observed rate of tumour regression was not driven by the addition of panitumumab.
“We feel this approach can be considered a new therapeutic option for locally advanced operable colon cancer,” Dr. Seymour said.
Discussant Jordan Berlin, MD, FASCO, of Vanderbilt University, thought the study results were promising. The safety data from FOxTROT support moving chemotherapy prior to surgery in patients with resectable colon cancer, with positive effects on complication and R1 resection rates, but the tradeoff is that some patients may be over treated.
“This is not practice changing in terms of standard of care, but it gives us a new option when we are thinking about our patients,” Dr. Berlin said.
Posted on
Previous Article
« Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC Next Article
Overcoming the challenges of immunotherapy in non–small cell lung cancer »
« Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC Next Article
Overcoming the challenges of immunotherapy in non–small cell lung cancer »
Table of Contents: ASCO 2019
Featured articles
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Breast Cancer
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer
Melanoma
Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma
Kidney Cancer
Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours
Sarcoma
Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint
Gastrointestinal Cancers
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases
Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer
Hematologic Malignancies
Daratumumab a promising treatment option for transplant-eligible multiple myeloma
Paediatric Oncology
Entrectinib produces rapid and durable responses in children with refractory CNS and solid tumours
Head and Neck Cancer
Ado-trastuzumab emtansine a potential new treatment option for HER2-amplified advanced salivary gland cancer
Sentinel lymph node biopsy shows promise for early oral cancer
Genitourinary Cancer - Prostate Cancer
Enzalutamide offers survival advantage over other NSAAs in mHSPC
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma
Multiple Myeloma
Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma
Lung Cancer
Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC
Overcoming the challenges of immunotherapy in non–small cell lung cancer
Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC
Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC
Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC
Lurbinectedin shows promise as second-line therapy for SCLC
Early results from TAK-788 in NSCLC with EGFR exon 20 insertions
Developmental Therapeutics - Immunotherapy
IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy